Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.

152 Background: In ARASENS, darolutamide (DARO) + androgen deprivation therapy (ADT) + docetaxel (DOC) significantly reduced risk of death by 32.5% vs placebo (PBO) + ADT + DOC in patients (pts) with mHSPC, with a similar incidence of treatment-emergent adverse events (TEAEs) between DARO and PBO treatment arms. DOC is associated with the risk of febrile neutropenia, which can be managed by DOC dose reduction and/or use of granulocyte colony …